JACC Specialty Journals

JACC Specialty Journals

American College of Cardiology
Country USA
Language EN
Episodes 1957
Latest 03.11.2026

In this podcast series, editors-in-chief from the JACC family of specialty journals provide highlights and summarize key findings for select issues. Published by the American College of Cardiology, the JACC Journals publish peer-reviewed articles on all aspects of cardiovascular disease, including original clinical studies, translational investigations with clear clinical relevance, state-of-the art papers, and review articles. They are top ranked for impact factor and their manuscripts are among the most covered by media outlets, most talked about on social media, and most read online.

Episodes

  • Plasma Proteins Associated with Incident Acute Myocardial Infarction in Asians with Type 2 Diabetes | JACC: Asia
    Plasma Proteins Associated with Incident Acute Myocardial Infarction in Asians with Type 2 Diabetes | JACC: Asia 03.11.2026 3m
    Commentary by Dr. Athanasios Sakalidis.
  • Real-World Evaluation of a Nationally Mandated Risk Stratification Tool for Destination Therapy LVAD in Japan | JACC: Asia
    Real-World Evaluation of a Nationally Mandated Risk Stratification Tool for Destination Therapy LVAD in Japan | JACC: Asia 03.11.2026 3m
    Commentary by Dr. Heerajnarain Bulluck.
  • Multimodality Imaging-Based Phenotyping and Prognostic Implications of Right Ventricular Involvement in Apical Hypertrophic Cardiomyopathy | JACC: Asia
    Multimodality Imaging-Based Phenotyping and Prognostic Implications of Right Ventricular Involvement in Apical Hypertrophic Cardiomyopathy | JACC: Asia 03.11.2026 4m
    Commentary by Dr. Milan Prsa.
  • Osteosarcopenia as a Risk Factor for Atrial Fibrillation: A Multi-Cohort Study | JACC: Asia
    Osteosarcopenia as a Risk Factor for Atrial Fibrillation: A Multi-Cohort Study | JACC: Asia 03.11.2026 3m
    Commentary by Dr. Yuhi Fujimoto.
  • Epidemiological Analysis and 2040 Projections of Atrial Fibrillation and Flutter in Asia | JACC: Asia
    Epidemiological Analysis and 2040 Projections of Atrial Fibrillation and Flutter in Asia | JACC: Asia 03.11.2026 4m
    Commentary by Dr. Yoshihiro Miyamoto.
  • Advances in a Capsule: October 2026 | JACC: Advances
    Advances in a Capsule: October 2026 | JACC: Advances 29.10.2026 9m
    Audio Summary of three articles from the October 2026 issue of JACC: Advances.
  • XGBoost Model with CMR Features for Prognostic Assessment in Patients With ST‑Segment Elevation Myocardial Infarction | JACC: Asia
    XGBoost Model with CMR Features for Prognostic Assessment in Patients With ST‑Segment Elevation Myocardial Infarction | JACC: Asia 20.10.2026 4m
    Commentary by Dr. Yoriyasu Suzuki.
  • Design and Rationale of GPS-CAD: Global Pretest Probability Study of Coronary Artery Disease | JACC: Asia
    Design and Rationale of GPS-CAD: Global Pretest Probability Study of Coronary Artery Disease | JACC: Asia 20.10.2026 4m
    Commentary by Dr. Junjie Yang.
  • Prediction of Paroxysmal Atrial Fibrillation with Incorporating Genomic Information Into AI-Based ECG Analysis | JACC: Asia
    Prediction of Paroxysmal Atrial Fibrillation with Incorporating Genomic Information Into AI-Based ECG Analysis | JACC: Asia 20.10.2026 3m
    Commentary by Dr. Qinkai Yu.
  • October 2026 Summary | JACC: CardioOncology
    October 2026 Summary | JACC: CardioOncology 20.10.2026 1m
    Editor-in-Chief Dr. Bonnie Ky introduces the October 2026 issue of JACC: CardioOncology, featuring Part 1 of a special focus on immunology and cardio-oncology. This issue brings together state-of-the-art reviews, primers, original research, and clinical cases examining the immune system's central role in cancer and cardiovascular disease. Topics include the mechanisms and clinical implications of cancer immunotherapies and the immune system's contributions to the cardiovascular effects of cytotoxic chemotherapy, with implications for scientific discovery and patient care.
  • Fibrotic Rewiring of CD8+ T-cells by Doxorubicin Drives Pathological Remodeling of Cardiac Extracellular Matrix | JACC: CardioOncology
    Fibrotic Rewiring of CD8+ T-cells by Doxorubicin Drives Pathological Remodeling of Cardiac Extracellular Matrix | JACC: CardioOncology 20.10.2026 2m
    Dr. Caitlin O'Meara discusses a JACC: CardioOncology study showing that doxorubicin reprograms CD8+ T cells into matrix-remodeling T cells (mxT-cells) that produce lysyl oxidase (LOX) and stiffen the cardiac extracellular matrix through HIF1α-P53-TGFβ signaling. She explains how this new immune mechanism of anthracycline cardiotoxicity could lead to therapies that prevent cardiac fibrosis, cardiomyopathy, and heart failure in patients treated with chemotherapy.
  • High-Sensitivity Cardiac Troponin T and I Discordance in Patients Receiving Immune Checkpoint Inhibitors | JACC: CardioOncology
    High-Sensitivity Cardiac Troponin T and I Discordance in Patients Receiving Immune Checkpoint Inhibitors | JACC: CardioOncology 20.10.2026 5m
    Dr. David Austin discusses a JACC: CardioOncology study showing that high-sensitivity cardiac troponin T was elevated in 37.9% of patients starting immune checkpoint inhibitor (ICI) therapy, compared with only 1.8% for high-sensitivity troponin I, a discordance linked to older age, male sex, and kidney dysfunction. He explains what this means for troponin assay selection, baseline testing, and ICI myocarditis surveillance, helping cardiologists and oncologists avoid unnecessary cancer treatment interruptions and immunosuppression.
  • Inflammatory Cell Profiles in Early- and Late-Manifestation Immune Checkpoint Inhibitor Myocarditis | JACC: CardioOncology
    Inflammatory Cell Profiles in Early- and Late-Manifestation Immune Checkpoint Inhibitor Myocarditis | JACC: CardioOncology 20.10.2026 3m
    Dr. Cristina Gil-Cruz discusses a JACC: CardioOncology study comparing early- and late-manifestation immune checkpoint inhibitor (ICI) myocarditis, where endomyocardial biopsies showed greater T-cell and macrophage infiltration in early cases despite similar left ventricular ejection fraction and fibrosis. She explains what these inflammatory cell profiles mean for cardio-oncology care, from immunosuppression and ICI rechallenge to balancing cardiac safety with effective cancer immunotherapy.
  • Impact of Device Position and Aortic Valve Prolapse on Outcomes After Transcatheter VSD Closure | JACC: Asia
    Impact of Device Position and Aortic Valve Prolapse on Outcomes After Transcatheter VSD Closure | JACC: Asia 07.10.2026 3m
    Commentary by Dr. Timothy Un.
  • Prognostic Impact of Residual Thrombus After Aspiration Thrombectomy in ST-Elevation Myocardial Infarction | JACC: Asia
    Prognostic Impact of Residual Thrombus After Aspiration Thrombectomy in ST-Elevation Myocardial Infarction | JACC: Asia 07.10.2026 4m
    Commentary by Dr. Ziyad Ghazzal.
  • Sex-Specific Lipid, Apolipoprotein B, and Lipoprotein(a) Responses to Berberine Based on 2 Randomized Placebo-Controlled Trials | JACC: Asia
    Sex-Specific Lipid, Apolipoprotein B, and Lipoprotein(a) Responses to Berberine Based on 2 Randomized Placebo-Controlled Trials | JACC: Asia 07.10.2026 3m
    Commentary by Dr. Yihang Fan.
  • Lifestyle and Metabolic Health, Low-Grade to Clinically Elevated Albuminuria, and Cardiovascular-Renal Diseases | JACC: Asia
    Lifestyle and Metabolic Health, Low-Grade to Clinically Elevated Albuminuria, and Cardiovascular-Renal Diseases | JACC: Asia 07.10.2026 3m
    Commentary by Dr. Hongmei Yan.
  • Efficacy and Safety of Quarterly Dosing SHR-1918 in Patients With Suboptimally Controlled Hyperlipidemia | JACC: Asia
    Efficacy and Safety of Quarterly Dosing SHR-1918 in Patients With Suboptimally Controlled Hyperlipidemia | JACC: Asia 07.10.2026 4m
    Commentary by Dr. Xiaojie Xie.
  • Oncologic Benefits and Cardiovascular Risks of Pembrolizumab: Insights From a Nationwide Lung Adenocarcinoma Cohort | JACC: Asia
    Oncologic Benefits and Cardiovascular Risks of Pembrolizumab: Insights From a Nationwide Lung Adenocarcinoma Cohort | JACC: Asia 06.10.2026 4m
    Commentary by Dr. Koohyar Ahmadzadeh.
  • Author Interview: Cholesterol Management Gaps Among Patients with Established Coronary Artery Disease Hospitalized for Acute Coronary Events | JACC: Advances
    Author Interview: Cholesterol Management Gaps Among Patients with Established Coronary Artery Disease Hospitalized for Acute Coronary Events | JACC: Advances 06.10.2026 24m
    Dinesh Kalra, Todd Villines, and Lisandro Colantonio discuss the importance of this article, what encouraged Dr. Colantonio to conduct this research, and how clinicians can address the concerns patients have.

Popular in

The podcast also appears in the podcast charts of these countries.